NPM1P17

Across TCGA pan-cancer cohorts, NPM1P17 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated NPM1P17 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher NPM1P17 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated NPM1P17 expression acts as an unfavorable survival marker, although some lineages such as OV and BLCA show a favorable association.

STAD, MESO, and ACC are the cancer types where NPM1P17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Quartile	II,III,IV	0.516	0.791	.001	109	view →
MESO	OS	Tertile	III,IV	0.036	0.563	<.001	63	view →
ACC	DFS	Tertile	IV	0.012	0.310	.002	60	view →
OV	OS	Tertile	IV	0.671	0.322	.013	36	view →
LIHC	DFS	Tertile	All	0.284	0.562	.008	36	view →
BLCA	OS	Tertile	II,III,IV	0.886	0.593	.016	21	view →
LUSC	DFS	Tertile	All	0.600	0.368	.006	18	view →
UCEC	OS	Tertile	All	0.593	0.687	.018	18	view →
CESC	DFS	Tertile	All	0.927	0.721	.027	12	view →
KIRP	OS	Tertile	All	0.830	0.950	.008	12	view →
SKCM	OS	Tertile	III,IV	0.777	0.375	.039	6	view →
READ	DFS	Tertile	III,IV	1.000	0.225	.040	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

NPM1P17–STAD (OS)

Open the STAD breakdown →